GlassScriptPhysician profile
David P Guss
NPI 1578595815
$4,694.03
in general payments reported to CMS, 2019-2025
38 companies · $765 in 2025
The $765 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $363 · 2021: $549 · 2022: $688 · 2023: $714 · 2024: $997 · 2025: $765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,476.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $835.44 | 2021-2025 | |
| Novo Nordisk INC | $603.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $462.21 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $279.85 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Janssen Pharmaceuticals, INC | $276.74 | 2019-2024 | Xarelto |
| Amgen INC. | $247.08 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $233.64 | 2019-2025 | Shingrix, Arexvy, Boostrix |
| Merck Sharp & Dohme LLC | $180.58 | 2019-2025 | Belsomra, Enflonsia, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.59 | 2021-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $160.31 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.64 | 2019-2022 | |
| Exact Sciences Corporation | $101.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $98.76 | 2019-2024 | |
| Pfizer INC. | $95.61 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.79 | 2019-2024 | Trintellix |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Guss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.